Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fold-in Synthesis of a Pentabenzopentaaza[10]circulene.
Matsuo Y, Kise K, Morimoto Y, Osuka A, Tanaka T. Matsuo Y, et al. Among authors: morimoto y. Angew Chem Int Ed Engl. 2022 Mar 7;61(11):e202116789. doi: 10.1002/anie.202116789. Epub 2022 Jan 20. Angew Chem Int Ed Engl. 2022. PMID: 34995398 Free article.
Hepatocyte β-Klotho regulates lipid homeostasis but not body weight in mice.
Kobayashi K, Tanaka T, Okada S, Morimoto Y, Matsumura S, Manio MC, Inoue K, Kimura K, Yagi T, Saito Y, Fushiki T, Inoue H, Matsumoto M, Nabeshima Y. Kobayashi K, et al. Among authors: morimoto y. FASEB J. 2016 Feb;30(2):849-62. doi: 10.1096/fj.15-274449. Epub 2015 Oct 29. FASEB J. 2016. PMID: 26514166
Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice.
Kurano M, Tsuneyama K, Morimoto Y, Nishikawa M, Yatomi Y. Kurano M, et al. Among authors: morimoto y. FASEB J. 2019 Apr;33(4):5181-5195. doi: 10.1096/fj.201801748R. Epub 2019 Jan 10. FASEB J. 2019. PMID: 30629456
ApoM may be useful as a therapeutic target to treat or retard the progression of IgA nephropathy.-Kurano, M., Tsuneyama, K., Morimoto, Y., Nishikawa, M., Yatomi, Y. Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice....
ApoM may be useful as a therapeutic target to treat or retard the progression of IgA nephropathy.-Kurano, M., Tsuneyama, K., Morimoto
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension.
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L; patisiran Global OLE study group. Adams D, et al. JAMA Neurol. 2025 Jan 13. doi: 10.1001/jamaneurol.2024.4631. Online ahead of print. JAMA Neurol. 2025. PMID: 39804640
2,430 results